Skip to main content
. Author manuscript; available in PMC: 2016 May 18.
Published in final edited form as: Oncogene. 2015 Apr 13;35(4):459–467. doi: 10.1038/onc.2015.97

Fig. 2. Pharmacological inhibition of B-Raf (e.g., with PLX4032) or MEK (e.g., with AZD6244 or PD0325901) suppresses DR5 expression in cancer cells (A-C); this effect is reversible upon stopping of the treatment (D).

Fig. 2

A and B, The indicated cancer cell lines were exposed to the given concentrations of the inhibitors as indicated for 16 h. C, TPC-1 cells were treated with 10 μM of the indicated inhibitors for different times as labeled. D, BCPAP cells were treated with 10 μM PLX4032 for 16 h. After removal of the medium, the cells were washed, re-fed with fresh medium and harvested at the indicated times. After these treatments, the cells were then harvested for preparation of whole-cell protein lysates and subsequent Western blotting to detect the indicated proteins.